Evidence map›Paper›PMID 32860457›Full record

SynthesisEuropean journal of clinical investigation2020

Features of severe COVID-19: A systematic review and meta-analysis.

Francesco Del Sole, Alessio Farcomeni, Lorenzo Loffredo, Roberto Carnevale, Danilo Menichelli, Tommasa Vicario, Pasquale Pignatelli, Daniele Pastori

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 10 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 10 syntheses or guidelines pooled it, 201 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Prevalence of post-traumatic stress symptoms among people influenced by coronavirus disease 2019 outbreak: A meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2021
    Pooled it
  8. A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19.International journal of environmental research and public health · 2020
    Pooled it
  9. Features of severe COVID-19: A systematic review and meta-analysis.European journal of clinical investigation · 2020
    Pooled it
  10. Pooled it
  11. Genetic Screening forFrontiers in immunology · 2021
    Trial
  12. Article
  13. Article
  14. Early Fc-effector antibody signatures impact COVID-19 disease trajectory.medRxiv : the preprint server for health sciences · 2026
    Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Francesco Del SoleI Clinica Medica, Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Alessio FarcomeniDepartment of Economics and Finance, University of Rome "Tor Vergata", Rome, Italy.
Lorenzo LoffredoI Clinica Medica, Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Roberto CarnevaleDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Danilo MenichelliI Clinica Medica, Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-9467-5903
Tommasa VicarioDepartment of General Surgery and Surgical Specialties "Paride Stefanini", Sapienza University of Rome, Rome, Italy.
Pasquale PignatelliI Clinica Medica, Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Daniele PastoriI Clinica Medica, Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0001-6357-5213
Sapienza University of Rome · ITClinica Mediterranea · ITPoliclinico Tor Vergata · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo systematically review clinical and biochemical characteristics associated with the severity of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19). MATERIALS AND

methodsSystematic review of observational studies from PubMed, ISI Web of Science, SCOPUS and Cochrane databases including people affected by COVID-19 and reporting data according to the severity of the disease. Data were combined with odds ratio (OR) and metanalysed. Severe COVID-19 was defined by acute respiratory distress syndrome, intensive care unit admission and death.

resultsWe included 12 studies with 2794 patients, of whom 596 (21.33%) had severe disease. A slightly higher age was found in severe vs non-severe disease. We found that prevalent cerebrovascular disease (odds ratio [OR] 3.66, 95% confidence interval [CI] 1.73-7.72), chronic obstructive pulmonary disease (OR: 2.39, 95% CI 1.10-5.19), prevalent cardiovascular disease (OR: 2.84, 95% CI 1.59-5.10), diabetes (OR: 2.78, 95% CI 2.09-3.72), hypertension (OR: 2.24, 95% CI 1.63-3.08), smoking (OR: 1.54, 95% CI 1.07-2.22) and male sex (OR: 1.22, 95% CI 1.01-1.49) were associated with severe disease. Furthermore, increased procalcitonin (OR: 8.21, 95% CI 4.48-15.07), increased D-Dimer (OR: 5.67, 95% CI 1.45-22.16) and thrombocytopenia (OR: 3.61, 95% CI 2.62-4.97) predicted severe infection.

conclusionCharacteristics associated with the severity of SARS-CoV-2 infection may allow an early identification and management of patients with poor outcomes.

Indexed as

BetacoronavirusCardiovascular DiseasesCerebrovascular DisordersComorbidityCoronavirus InfectionsCOVID-19Diabetes MellitusFibrin Fibrinogen Degradation ProductsHumansHypertensionPandemicsPneumonia, ViralPrevalenceProcalcitoninPulmonary Disease, Chronic ObstructiveRisk FactorsFibrin Fibrinogen Degradation Productsfibrin fragment DProcalcitonind-dimerinfectionprocalcitoninSARS-CoV-2severitysexthrombocytopenia

Identifiers

PMID32860457
PMCPMC7435565
OpenAlexW3048085407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.